CN105902762A - Pharmaceutical composition for treating primary hypertension and preparation method and application thereof - Google Patents

Pharmaceutical composition for treating primary hypertension and preparation method and application thereof Download PDF

Info

Publication number
CN105902762A
CN105902762A CN201610443209.4A CN201610443209A CN105902762A CN 105902762 A CN105902762 A CN 105902762A CN 201610443209 A CN201610443209 A CN 201610443209A CN 105902762 A CN105902762 A CN 105902762A
Authority
CN
China
Prior art keywords
parts
radix
pharmaceutical composition
essential hypertension
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610443209.4A
Other languages
Chinese (zh)
Inventor
衣振兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610443209.4A priority Critical patent/CN105902762A/en
Publication of CN105902762A publication Critical patent/CN105902762A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating primary hypertension and a preparation method and application thereof and belongs to the technical field of traditional Chinese medicine. The pharmaceutical composition is prepared from, by weight, 20-25 parts of radix astragali, 10-15 parts of retinervus luffae fructus, 2-4 parts of crinis carbonisatus, 15-20 parts of radix salviae miltiorrhizae, 15-20 parts of radix achyranthis bidentatae, 5-8 parts of fructus schisandrae chinensis, 10-15 parts of radix notoginseng, 10-15 parts of radix paeoniae rubra, 5-8 parts of chicken gizzard membranes, 15-20 parts of rhizoma atractylodis macrocephalae, 15-20 parts of common yam rhizomes, 15-20 parts of poria cocos, 6-10 parts of semen persicae, 14-18 parts of radix polygoni multiflori and 10-15 parts of radix angelica sinensis. The traditional Chinese medicine is under reasonable compatibility; by improving all viscera functions and promoting circulation of qi and blood, the internal yin and yang are balanced, genuine qi is strengthened, inherence is consolidated, phlegm is not prone to gather, and the effects of removing stasis and phlegm and eliminating stagnation; the medicine can radically treat primary hypertension, and primary hypertension is not prone to relapse after treatment; old and fat people are a high risk group of hypertension, and the medicine can also be used by the high risk group for prevention.

Description

A kind of pharmaceutical composition treating essential hypertension and preparation method and application
Technical field
The present invention relates to tcm field, a kind of pharmaceutical composition treating essential hypertension and preparation method thereof And application.
Background technology
Hypertension is a kind of persistently to rise the general chronic disease of a height of master with circulation arteriotony, have in recent years age of onset by The trend gradually reduced, it is higher that long-term psychentonia lacks physical exertion, inherited genetic factors, obesity, Sal too much person sickness rate.Mesh The front medicine for blood pressure lowering is numerous, and especially in the majority with Western medicine, Western medicine has the biggest side effect and bigger dependency in the treatment, The mechanism of Western medicine is that to expand blood vessel be main, and blood vessel dies down at continuous process of expansion Elastic and hardens, hence in so that for a long time The people using depressor easily causes sclerosis of blood vessels and rupturing, and causes the disease such as cerebral vessels embolism, apoplexy, also utilize pure in Medicine is treated, but therapeutic effect is the most undesirable, and therefore, existing Drug therapy can not fundamentally treat constitutional Hypertension, therefore, in the urgent need to the medicine of a kind for the treatment of essential hypertension that can thoroughly remove old complaint of research.
Summary of the invention
For solving the defect that prior art exists, can remove, it is desirable to provide a kind of, the fat that Ink vessel transfusing is piled up, reduce blood Fat content and blood viscosity, pharmaceutical composition for the treatment of essential hypertension of vessel softening and preparation method and application.
To achieve these goals, the technical scheme is that
A kind of pharmaceutical composition treating essential hypertension, its effective ingredient includes the raw material of following weight portion: Radix Astragali 20-25 Part, Retinervus Luffae Fructus 10-15 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 15-20 part, Radix Achyranthis Bidentatae 15-20 part, Fructus Schisandrae Chinensis 5-8 part, Radix Notoginseng 10-15 part, Radix Paeoniae Rubra 10-15 part, Endothelium Corneum Gigeriae Galli 5-8 part, Rhizoma Atractylodis Macrocephalae 15-20 part, Rhizoma Dioscoreae 15-20 part, Poria 15-20 part, Semen Persicae 6-10 part, Radix Polygoni Multiflori 14-18 part, Radix Angelicae Sinensis 10-15 part.
The present invention also has a following additional technical feature:
Preferably, its effective ingredient includes the raw material of following weight portion: Radix Astragali 22-25 part, Retinervus Luffae Fructus 12-14 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 17-20 part, Radix Achyranthis Bidentatae 17-20 part, Fructus Schisandrae Chinensis 5-7 part, Radix Notoginseng 12-15 part, Radix Paeoniae Rubra 13-15 part, chicken Endothelium corneum 6-8 part, Rhizoma Atractylodis Macrocephalae 15-17 part, Rhizoma Dioscoreae 15-18 part, Poria 15-20 part, Semen Persicae 6-8 part, Radix Polygoni Multiflori 15-17 part, Radix Angelicae Sinensis 12-13 part.
Preferably, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 23 parts, Retinervus Luffae Fructus 13 parts, Crinis Carbonisatus 3 parts, Radix Salviae Miltiorrhizae 18 parts, Radix Achyranthis Bidentatae 18 parts, Fructus Schisandrae Chinensis 6 parts, Radix Notoginseng 13 parts, Radix Paeoniae Rubra 14 parts, Endothelium Corneum Gigeriae Galli 7 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, mountain Medicine 17 parts, 17 parts of Poria, 7 parts of Semen Persicae, Radix Polygoni Multiflori 16 parts, Radix Angelicae Sinensis 13 parts.
Preferably, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 22 parts, Retinervus Luffae Fructus 14 parts, Crinis Carbonisatus 2 parts, Radix Salviae Miltiorrhizae 20 parts, Radix Achyranthis Bidentatae 17 parts, Fructus Schisandrae Chinensis 7 parts, Radix Notoginseng 12 parts, Radix Paeoniae Rubra 15 parts, Endothelium Corneum Gigeriae Galli 6 parts, the Rhizoma Atractylodis Macrocephalae 17 parts, mountain Medicine 15 parts, 20 parts of Poria, 6 parts of Semen Persicae, Radix Polygoni Multiflori 17 parts, Radix Angelicae Sinensis 12 parts.
The present invention also provides for the preparation method of the pharmaceutical composition of above-mentioned treatment essential hypertension, comprises the following steps: by place Side amount weigh the Radix Astragali, Retinervus Luffae Fructus, Crinis Carbonisatus, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Fructus Schisandrae Chinensis, Radix Notoginseng, Radix Paeoniae Rubra, Endothelium Corneum Gigeriae Galli, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae, Poria, Semen Persicae, Radix Polygoni Multiflori, add the water of material gross mass 4-8 times quality, after first intense fire decocts boiling, change after Radix Angelicae Sinensis mixing With slow fire boiling 30-40 minute, being filtrated to get medicinal liquid for the first time, medicinal residues boiling again boiling obtains second time medicine for 10 minutes Liquid, merges medicinal liquid, filtration, filtrate and get final product.
Further, the preparation method of the pharmaceutical composition of above-mentioned treatment essential hypertension, comprise the following steps: weigh Huang Stilbene 23g, Retinervus Luffae Fructus 13g, Crinis Carbonisatus 3g, Radix Salviae Miltiorrhizae 18g, Radix Achyranthis Bidentatae 18g, Fructus Schisandrae Chinensis 6g, Radix Notoginseng 13g, Radix Paeoniae Rubra 14g, chicken Endothelium corneum 7g, Rhizoma Atractylodis Macrocephalae 16g, Rhizoma Dioscoreae 17g, Poria 17g, Semen Persicae 7g, Radix Polygoni Multiflori 16g, Radix Angelicae Sinensis 13g, add 1kg water soaking After 1 hour, after intense fire decocts boiling, using slow fire boiling instead 30-40 minute, be filtrated to get medicinal liquid for the first time, medicinal residues add again The boiling of 400g soak by water obtains second time medicinal liquid for 10 minutes, merges medicinal liquid, filtration, filtrate and get final product.
Concrete, filtrate is 800ml, takes at twice, the most once.
Preferably, also include gained filtrate is condensed into cream, add pharmaceutically acceptable adjuvant, according to pharmaceutically conventional preparation Technique makes form of Chinese drug.
Preferably, described form of Chinese drug is tablet, pill, capsule, granule, powder or solution.
Further, described pharmaceutically acceptable adjuvant includes starch, Pulvis Talci, magnesium stearate, glucose, Mel, paste Essence, polyvinyl alcohol, Carboxymethyl cellulose sodium, sodium benzoate.
The present invention also provides for the pharmaceutical composition of above-mentioned treatment essential hypertension in the medicine of preparation treatment essential hypertension Application.
The invention have the benefit that the drug matching of the present invention is reasonable, after cooperation, improve each function, promote QI and blood fortune OK, making internal equilibrium between yin and yang, the most just holding up this, turbid being difficult to of expectorant is gathered, and reaches blood stasis dispelling expectorant, eliminates the effect of numbness resistance；The present invention Medicine can be rapid-action from the most thoroughly treating essential hypertension, effective, be difficult to after treatment recurrence；Older, fat Being the high-risk group of hypertension, the medicine of the present invention also can do prevention and be used for high-risk group.
The additional aspect of the present invention and advantage will part be given in the following description, and part will become apparent from the description below, Or recognized by the practice of the present invention.
Detailed description of the invention
The invention discloses a kind of pharmaceutical composition treating essential hypertension and preparation method thereof, those skilled in the art are permissible Use for reference present disclosure, be suitably modified technological parameter and realize.Special needs to be pointed out is, all similar replacements and change are to ability Being apparent from for field technique personnel, they are considered as being included in the present invention.Method and the application of the present invention have been passed through Preferred embodiment is described, and related personnel substantially can be to as herein described in without departing from present invention, spirit and scope Methods and applications.
Embodiment 1
The preparation method of a kind of pharmaceutical composition treating essential hypertension, weighs Radix Astragali 23g, Retinervus Luffae Fructus 13g, Crinis Carbonisatus 3g, Radix Salviae Miltiorrhizae 18g, Radix Achyranthis Bidentatae 18g, Fructus Schisandrae Chinensis 6g, Radix Notoginseng 13g, Radix Paeoniae Rubra 14g, Endothelium Corneum Gigeriae Galli 7g, Rhizoma Atractylodis Macrocephalae 16g, Rhizoma Dioscoreae 17g, Poria 17g, Semen Persicae 7g, Radix Polygoni Multiflori 16g, Radix Angelicae Sinensis 13g, addition 1kg water soaking, after 1 hour, after intense fire decocts boiling, changes With slow fire boiling 35 minutes, being filtrated to get 500ml medicinal liquid for the first time, medicinal residues again add the boiling of 400g soak by water and obtain for 10 minutes 300ml second time medicinal liquid, merges medicinal liquid, filtration, obtains 800ml filtrate, take at twice, the most once.
Embodiment 2
The preparation method of a kind of pharmaceutical composition treating essential hypertension, weighs Radix Astragali 22g, Retinervus Luffae Fructus 14g, Crinis Carbonisatus 2g, Radix Salviae Miltiorrhizae 20g, Radix Achyranthis Bidentatae 17g, Fructus Schisandrae Chinensis 7g, Radix Notoginseng 12g, Radix Paeoniae Rubra 15g, Endothelium Corneum Gigeriae Galli 6g, Rhizoma Atractylodis Macrocephalae 17g, Rhizoma Dioscoreae 15g, Poria 20g, Semen Persicae 6g, Radix Polygoni Multiflori 17g, Radix Angelicae Sinensis 12g, addition 1.2kg water soaking is after 1 hour, after intense fire decocts boiling, Using slow fire boiling instead 35 minutes, be filtrated to get 700ml medicinal liquid for the first time, medicinal residues again add 300g soak by water and seethe with excitement 10 minutes To 250ml second time medicinal liquid, merge medicinal liquid, filtration, obtain 950ml filtrate, take at twice, the most once.
Embodiment 3
The preparation method of a kind of pharmaceutical composition treating essential hypertension, weighs Radix Astragali 20g, Retinervus Luffae Fructus 10g, Crinis Carbonisatus 4g, Radix Salviae Miltiorrhizae 20g, Radix Achyranthis Bidentatae 20g, Fructus Schisandrae Chinensis 5g, Radix Notoginseng 15g, Radix Paeoniae Rubra 12g, Endothelium Corneum Gigeriae Galli 8g, Rhizoma Atractylodis Macrocephalae 19g, Rhizoma Dioscoreae 19g, Poria 20g, Semen Persicae 10g, Radix Polygoni Multiflori 18g, Radix Angelicae Sinensis 15g, addition 1.2kg water soaking is after 1 hour, after intense fire decocts boiling, Using slow fire boiling instead 40 minutes, be filtrated to get 700ml medicinal liquid for the first time, medicinal residues again add 300g soak by water and seethe with excitement 10 minutes To 250ml second time medicinal liquid, merge medicinal liquid, filtration, obtain 950ml filtrate, take at twice, the most once.
Embodiment 4
When the medicinal liquid obtained in embodiment 1 is placed in rotary evaporator, under the conditions of 50 DEG C, concentrating under reduced pressure becomes 50 DEG C, relative density is The ointment of 1.2, ointment adds conventional pharmaceutical adjuvants and is prepared as tablet according to common process.
Embodiment 5
The ointment obtained in embodiment 4 addition conventional pharmaceutical adjuvants is prepared as pill according to common process.
Embodiment 6
The ointment obtained in embodiment 4 addition conventional pharmaceutical adjuvants is prepared as granule according to common process.
Embodiment 7 clinical trial
100 hyperpietics of hospital being carried out random packet, often organizes 50 examples, A group takes embodiments of the invention 1 preparation Decoction, B group takes drugs compared, and comparative example is Western medicine, observes 3 months, takes blood pressure with blood pressure measuring, according to each age group Normal Value judges whether to recover normal.
The present invention is as shown in table 1 with the therapeutic effect of comparative example:
Table 1 Comparison of therapeutic
Table 1 is visible, and the medicine of the present invention is compared with comparative example 1, and cure rate reaches 98% apparently higher than comparative example, total effective rate, And without any side effects, after healing, to observe not recurrence half a year, take the medicine of comparative example, pressure value is unstable, neglects Height is the lowest, if drug withdrawal, then pressure value can raise again, and its cure rate is felt all not as the medicine of the present invention with taking.
From table 1 it follows that the medicine of the present invention can cure most patients in 3 months, short as the time, cure effect The best, after healing, continue to strengthen the medicine 20 days taking the present invention.
Concrete case:
Bent certain, man, 25 years old, master, mother had hypertension, belongs to essential hypertension, when 22 years old, after the most drunk Show hypertension symptom, hereafter 3 years, every pressure big or nervous time headache symptom will occur, detection pressure value is high Pressure 170mmhg, due to headache, delays many courses, takes Western medicine, and other Chinese medicines are not got better and turned, and take the present invention Medicine after, number of times and the degree of a month headache have alleviated, and three months pressure values recover normal, and continual cure is consolidated One month, after observing 1 year, have no recurrence.
Zhang, female, 67 years old, retired staff, body weight 150 jin, easy fat body constitution, essential hypertension, pressure value high pressure 180mmhg, Ill 9 years, dizzy, insomnia is serious, numbness of hands and feet, irritated insomnia, takes treatment hypertension drug, after healing, no always Going out 1 year and can recur again, after taking the medicine of the present invention, three months, pressure value recovered normal, has no recurrence after observing 1 year.
The above is only the preferred embodiment of the present invention, it is noted that for those skilled in the art, Under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications, these improvements and modifications also should be regarded as this Bright protection domain.

Claims (8)

1. the pharmaceutical composition treating essential hypertension, it is characterized in that, its effective ingredient includes the raw material of following weight portion: Radix Astragali 20-25 part, Retinervus Luffae Fructus 10-15 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 15-20 part, Radix Achyranthis Bidentatae 15-20 part, Fructus Schisandrae Chinensis 5-8 part, Radix Notoginseng 10-15 part, Radix Paeoniae Rubra 10-15 part, Endothelium Corneum Gigeriae Galli 5-8 part, Rhizoma Atractylodis Macrocephalae 15-20 part, Rhizoma Dioscoreae 15-20 part, Poria 15-20 part, Semen Persicae 6-10 part, Radix Polygoni Multiflori 14-18 part, Radix Angelicae Sinensis 10-15 part.
The pharmaceutical composition for the treatment of essential hypertension the most according to claim 1, it is characterized in that, its effective ingredient includes the raw material of following weight portion: Radix Astragali 22-25 part, Retinervus Luffae Fructus 12-14 part, Crinis Carbonisatus 2-4 part, Radix Salviae Miltiorrhizae 17-20 part, Radix Achyranthis Bidentatae 17-20 part, Fructus Schisandrae Chinensis 5-7 part, Radix Notoginseng 12-15 part, Radix Paeoniae Rubra 13-15 part, Endothelium Corneum Gigeriae Galli 6-8 part, Rhizoma Atractylodis Macrocephalae 15-17 part, Rhizoma Dioscoreae 15-18 part, Poria 15-20 part, Semen Persicae 6-8 part, Radix Polygoni Multiflori 15-17 part, Radix Angelicae Sinensis 12-13 part.
The pharmaceutical composition for the treatment of essential hypertension the most according to claim 2, it is characterized in that, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 23 parts, Retinervus Luffae Fructus 13 parts, Crinis Carbonisatus 3 parts, Radix Salviae Miltiorrhizae 18 parts, Radix Achyranthis Bidentatae 18 parts, Fructus Schisandrae Chinensis 6 parts, Radix Notoginseng 13 parts, Radix Paeoniae Rubra 14 parts, Endothelium Corneum Gigeriae Galli 7 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, Rhizoma Dioscoreae 17 parts, 17 parts of Poria, 7 parts of Semen Persicae, Radix Polygoni Multiflori 16 parts, Radix Angelicae Sinensis 13 parts.
The pharmaceutical composition for the treatment of essential hypertension the most according to claim 2, it is characterized in that, its effective ingredient includes the raw material of following weight portion: the Radix Astragali 22 parts, Retinervus Luffae Fructus 14 parts, Crinis Carbonisatus 2 parts, Radix Salviae Miltiorrhizae 20 parts, Radix Achyranthis Bidentatae 17 parts, Fructus Schisandrae Chinensis 7 parts, Radix Notoginseng 12 parts, Radix Paeoniae Rubra 15 parts, Endothelium Corneum Gigeriae Galli 6 parts, the Rhizoma Atractylodis Macrocephalae 17 parts, Rhizoma Dioscoreae 15 parts, 20 parts of Poria, 6 parts of Semen Persicae, Radix Polygoni Multiflori 17 parts, Radix Angelicae Sinensis 12 parts.
5. the preparation method of the pharmaceutical composition of the treatment essential hypertension described in any one of claim 1-4, it is characterized in that, comprise the following steps: weigh the Radix Astragali by recipe quantity, Retinervus Luffae Fructus, Crinis Carbonisatus, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Fructus Schisandrae Chinensis, Radix Notoginseng, Radix Paeoniae Rubra, Endothelium Corneum Gigeriae Galli, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae, Poria, Semen Persicae, Radix Polygoni Multiflori, the water of material gross mass 4-8 times quality is added after Radix Angelicae Sinensis mixing, after first intense fire decocts boiling, use slow fire boiling instead 30-40 minute, it is filtrated to get medicinal liquid for the first time, medicinal residues boiling again boiling obtains second time medicinal liquid for 10 minutes, merge medicinal liquid, filter, filtrate and get final product.
The preparation method of the pharmaceutical composition for the treatment of essential hypertension the most according to claim 5, it is characterised in that also include gained filtrate is condensed into cream, add pharmaceutically acceptable adjuvant, make form of Chinese drug according to pharmaceutically conventional fabrication process.
The preparation method of the pharmaceutical composition for the treatment of essential hypertension the most according to claim 6, it is characterised in that described form of Chinese drug is tablet, pill, capsule, granule, powder or solution.
8. the pharmaceutical composition of the treatment essential hypertension described in any one of claim 1-4 application in the medicine of preparation treatment essential hypertension.
CN201610443209.4A 2016-06-18 2016-06-18 Pharmaceutical composition for treating primary hypertension and preparation method and application thereof Withdrawn CN105902762A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610443209.4A CN105902762A (en) 2016-06-18 2016-06-18 Pharmaceutical composition for treating primary hypertension and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610443209.4A CN105902762A (en) 2016-06-18 2016-06-18 Pharmaceutical composition for treating primary hypertension and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN105902762A true CN105902762A (en) 2016-08-31

Family

ID=56758128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610443209.4A Withdrawn CN105902762A (en) 2016-06-18 2016-06-18 Pharmaceutical composition for treating primary hypertension and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN105902762A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038925A (en) * 2016-08-10 2016-10-26 衣明春 Medicinal composition for treating primary hypertension, and preparation method and application thereof
CN106421603A (en) * 2016-10-26 2017-02-22 黔西南州神力中草药应用开发研究所 Medicine for treating cardiovascular disease and preparation method thereof
CN106511903A (en) * 2016-12-15 2017-03-22 山东中医药大学附属医院 Composition for assisting diuretic in treating old age hypertension and improving compliance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103920032A (en) * 2014-04-04 2014-07-16 牡丹江医学院 Medicine for treating essential hypertension and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103920032A (en) * 2014-04-04 2014-07-16 牡丹江医学院 Medicine for treating essential hypertension and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038925A (en) * 2016-08-10 2016-10-26 衣明春 Medicinal composition for treating primary hypertension, and preparation method and application thereof
CN106421603A (en) * 2016-10-26 2017-02-22 黔西南州神力中草药应用开发研究所 Medicine for treating cardiovascular disease and preparation method thereof
CN106511903A (en) * 2016-12-15 2017-03-22 山东中医药大学附属医院 Composition for assisting diuretic in treating old age hypertension and improving compliance

Similar Documents

Publication Publication Date Title
CN1850217B (en) Compounded preparation for treating fatty liver and preparing method
CN105902762A (en) Pharmaceutical composition for treating primary hypertension and preparation method and application thereof
CN102068585B (en) Chinese medicinal compound preparation for treating chronic nephritis and nephrotic syndromes
CN100381163C (en) Medicine comprising rilmenidine
CN101601740B (en) Medicament for treating myasthenia gravis and preparation method thereof
CN106421727A (en) Traditional Chinese medicine composition for treating painful menstruation and preparation method and application thereof
CN101773657B (en) Medicine containing sodium nitroprusside
CN101732688B (en) Amlodipine-containing medicament
CN103494939A (en) Traditional Chinese medicine for treating senile habitual constipation
CN106038925A (en) Medicinal composition for treating primary hypertension, and preparation method and application thereof
CN102805795B (en) Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof
CN101732689B (en) Minoxidil-containing medicament
CN101708326B (en) Medicine containing nifedipine
CN101708325B (en) Medicine containing propranolol
CN106361874A (en) Yao medicine semiliquidambar cathayensis compound preparation for treating migrating gout and preparation method of semiliquidambar cathayensis compound preparation
CN100367956C (en) Medicine for treating hypertension
CN102451330A (en) Traditional Chinese medicine for treating sterility due to blood stasis
CN101502635B (en) Medicament composition containing Reserpine
CN1250274C (en) Medicine for abstinence of drugs and rehabilitation, and preparing process thereof
CN101810839B (en) Diltiazem-containing medicine
CN101732687B (en) Methyldopa-containing medicament
CN101810840B (en) Medicament containing terazosin
CN101773658B (en) Medicine containing indapamide
CN104491316A (en) Traditional Chinese medicine preparation for treating middle-warmer energy insufficiency type prostate hyperplasia
CN101732686B (en) Metoprolol-containing medicament

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160831

WW01 Invention patent application withdrawn after publication